However, endocrine therapies such as tamoxifen or aromatase inhibitors are effective across aging groups in treating hormone receptor-positive (HR+) cancers, as shown by clinical trials such as ATAC and BIG 1-98. This evidence concerns the gene CYP19A1 and cancer.